<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="pola-rchp-polarix-ineligible-low-risk-dlbcl-ren-pf984">
    <meta name="study:title" content="PF984 - Pola-R-CHP performed well in POLARIX trial-ineligible and low risk (IPI 0-1) patients with previously untreated DLBCL: A prospective observational study">
    <meta name="study:fileName" content="Abstracts/POLA-RCHP-POLARIX-INELIGIBLE-LOW-RISK-DLBCL-REN-PF984.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Clinical trial"> <meta name="study:drugs" content="Polatuzumab Vedotin,ADC,Rituximab,Monoclonal Antibody,Chemotherapy,CIT,Pola-RCHP">

    <title>PF984: Pola-R-CHP in POLARIX-Ineligible & Low-Risk DLBCL (Ren) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PF984 - Pola-R-CHP in POLARIX-Ineligible & Low-Risk DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=117)</h4>
                    <p>Untreated DLBCL: Low-risk (IPI 0-1) or POLARIX-ineligible. Aim: Evaluate Pola-R-CHP efficacy & safety.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention</h4>
                    <p>Pola-R-CHP regimen x6 cycles (standard doses). Prospective observational study.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (6 Cycles, N=72)</h4>
                    <p>Overall CRR: <span class="highlight-value">80.6%</span><br>IPI 0-1 CRR (N=12 from image): <span class="highlight-value">91.7%</span><br>POLARIX-Ineligible CRR (N=34 from image): <span class="highlight-value">73.5%</span></p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Manageable safety. G3-5 AEs: Lung infection (20.5%), Neutropenia (17.9%). Pola-R-CHP performed well in these populations.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PF984 - Pola-R-CHP performed well in POLARIX trial-ineligible and low risk (IPI 0-1) patients with previously untreated DLBCL: A prospective observational study</h1>
            <p class="abstract-sub-header">Yuhong Ren, Luya Cheng, Jingli Zhuang, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PF984 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Pola-R-CHP showed increased 5-year PFS in untreated DLBCL with IPI 2-5 (POLARIX study).</li>
                        <li>Limited evidence for Pola-R-CHP in patients outside POLARIX criteria (e.g., IPI 0-1, specific comorbidities).</li>
                        <li>Need to elucidate efficacy/safety in all DLBCL patients in real-world settings.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To investigate the efficacy and safety of Pola-R-CHP in untreated adult DLBCL patients of low risk (IPI 0-1) or ineligible for POLARIX trial.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Prospective observational cohort study (NCT06203652) at Zhongshan Hospital, Fudan University.</li>
                        <li>Enrollment: April 1, 2023 - Oct 31, 2024. N=117 successive DLBCL patients.</li>
                        <li>Inclusion: ≥1 cycle Pola-R-CHP as 1L, >18 years, informed consent. Comorbidities not excluded.</li>
                        <li>Intervention: Polatuzumab 1.8 mg/kg, Rituximab 375 mg/m², Cyclophosphamide 750 mg/m², Doxorubicin 50 mg/m² (all IV D1); Prednisone 100 mg PO QD (D1-5). q21d x 6 cycles.</li>
                        <li>Assessment: PET/CT or CT every 3 cycles. If SD/PD after 3 cycles, 2L treatment.</li>
                        <li>Response: Lugano 2014. AEs: NCI-CTCAE 5.0.</li>
                        <li>Primary Endpoint: CR rate after 6 cycles of Pola-R-CHP.</li>
                        <li>Secondary Endpoints: Safety, 12-month PFS.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Study Flow Overview</h3>
                        <div class="schema-enrollment">
                            <strong>Successive DLBCL Patients (N=117 Enrolled)</strong>
                            <span>(≥1 cycle Pola-R-CHP as 1L)</span>
                            <span>Low Risk (IPI 0-1) or POLARIX-Ineligible</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase">
                                <strong>Pola-R-CHP Regimen (q21d x 6 cycles planned)</strong>
                                <span>Polatuzumab vedotin: 1.8 mg/kg IV (D1)</span>
                                <span>Rituximab: 375 mg/m² IV (D1)</span>
                                <span>Cyclophosphamide: 750 mg/m² IV (D1)</span>
                                <span>Doxorubicin: 50 mg/m² IV (D1)</span>
                                <span>Prednisone: 100 mg PO (D1-5)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Assessment every 3 cycles (PET/CT or CT)</span>
                           <span>Primary Endpoint: CR rate at 6 cycles</span>
                           <span>Secondary: Safety, 12-month PFS</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=117 Enrolled)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Median Age, years (range)</td><td>56 (18-76)</td></tr>
                                <tr><td>IPI 0-1, n (%)</td><td>24 (20.5%)</td></tr>
                                <tr><td>Performance Status 2-4, n (%)</td><td>32 (27.4%)</td></tr>
                                <tr><td>POLARIX Trial-Ineligible (at baseline), n (%)</td><td>57 (48.7%)</td></tr>
                                </tbody>
                        </table>
                         <p class="footnote-text mt-1">72 patients completed 6 cycles of Pola-R-CHP.</p>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (Median F/U: 7.1 months)</h2>
                    <p class="text-sm mb-2">Primary Endpoint (CR rate after 6 cycles):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li><strong>All patients (N=72 completed 6 cycles): 80.6%</strong></li>
                        <li>Low risk (IPI 0-1) subgroup (N=12 from image): 91.7%</li>
                        <li>POLARIX trial-ineligible subgroup (N=34 from image): 73.5%</li>
                    </ul>
                     <p class="text-sm mb-2">12-Month PFS Rate:</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>All patients (N=72 cohort): 90.5%</li>
                        <li>Low risk (IPI 0-1) subgroup: 100.0%</li>
                        <li>POLARIX trial-ineligible subgroup: 88.4%</li>
                    </ul>
                    <p class="text-xs meta-info mb-1">Median PFS and OS not reached in all groups.</p>
                    <div class="chart-container mb-6">
                        <svg id="polaRchpPolarixIneligibleResponseChart" width="450" height="320"></svg>
                        <div id="polaRchpPolarixIneligibleResponseLegend" class="legend"></div>
                        <p class="text-xs meta-info mt-2">Data for CR/PR at 6 Cycles based on provided image (Figure 1 in abstract).</p>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (N=117)</h2>
                    <p class="text-sm mb-2">Most common Grade 3-5 Adverse Events:</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-2 safety-table">
                        <li>Lung infection: 20.5%</li>
                        <li>Neutropenia: 17.9%</li>
                        <li>Leukopenia: 12.8%</li>
                    </ul>
                    <p class="text-sm mb-1">Most patients recovered with best supportive care.</p>
                    <p class="text-sm mb-1">Peripheral neuropathy: 20 patients (19/20 were Grade 1-2).</p>
                    <p class="text-sm">Dose de-escalation/discontinuation of polatuzumab vedotin:</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2 safety-table">
                        <li>4 patients in trial-ineligible group.</li>
                        <li>1 patient in trial-eligible group.</li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Pola-R-CHP performed well in POLARIX trial-ineligible and low-risk (IPI 0-1) DLBCL patients as first-line therapy in this real-world prospective cohort.</li>
                <li>Safety profiles were manageable, even in patients ineligible for POLARIX trial.</li>
                <li>Ongoing treatment and follow-up will be further updated.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>1L, First-Line; AE, Adverse Event; CI, Confidence Interval; CR, Complete Response; CT, Computed Tomography; DLBCL, Diffuse Large B-Cell Lymphoma; FDG, Fluorodeoxyglucose; F/U, Follow-up; G, Grade; IPI, International Prognostic Index; IV, Intravenous; KG, Kilogram; m2, Square Meter; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; ORR, Overall Response Rate; OS, Overall Survival; PET, Positron Emission Tomography; PFS, Progression-Free Survival; Pola, Polatuzumab vedotin; PO, Per Os (by mouth); QD, Once a day; R-CHP, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; SD, Stable Disease.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Ren Y, Cheng L, Zhuang J, et al. Pola-R-CHP performed well in POLARIX trial-ineligible and low risk (IPI 0-1) patients with previously untreated DLBCL: A prospective observational study. Abstract #PF984 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PF984 | Abstract Release: 05/14/2025 | Presentation: 06/13/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    <script>
        function drawGroupedBarChartForPF984(containerId, legendContainerId) {
            const chartTitle = "CR & PR Rates at 6 Cycles by Subgroup";
            // Data extracted from the provided image (Figure 1) for 6 Cycles
            const chartData = [
                { group: "All (N=72)", values: { CR: 80.6, PR: 5.6 }, orr: 86.2 }, // 80.6 + 5.6 = 86.2
                { group: "IPI 0-1 (N=12)", values: { CR: 91.7, PR: 8.3 }, orr: 100.0 }, // 91.7 + 8.3 = 100.0
                { group: "POLARIX-Ineligible (N=34)", values: { CR: 73.5, PR: 5.9 }, orr: 79.4 } // 73.5 + 5.9 = 79.4
            ];

            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);

            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 450;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.95, 350);
            }
            
            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");

            const margin = { top: 50, right: 20, bottom: 60, left: 60 }; // Increased bottom margin for labels
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <=0) return;

            const g = svg.append("g")
                .attr("transform", `translate(${margin.left},${margin.top})`);

            const groups = chartData.map(d => d.group); 
            const subgroups = ["CR", "PR"]; 
            
            const xScaleGroups = d3.scaleBand()
                .domain(groups)
                .range([0, chartWidth])
                .padding(0.25);

            const xScaleSubgroups = d3.scaleBand()
                .domain(subgroups)
                .range([0, xScaleGroups.bandwidth()])
                .padding(0.05);

            const yScale = d3.scaleLinear()
                .domain([0, 100])
                .range([chartHeight, 0]);

            const color = d3.scaleOrdinal()
                .domain(subgroups)
                .range(["var(--sobi-teal)", "var(--sobi-yellow)"]);

            g.append("g")
                .attr("transform", `translate(0,${chartHeight})`)
                .call(d3.axisBottom(xScaleGroups))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px")
                .attr("transform", "rotate(-20) translate(-5,0)") // Rotate labels
                .style("text-anchor", "end");


            g.append("g")
                .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px");

            g.append("g")			
                .attr("class", "grid")
                .call(d3.axisLeft(yScale)
                    .ticks(5)
                    .tickSize(-chartWidth)
                    .tickFormat("")
                )
                .selectAll("line")
                .style("stroke", "#e0e0e0")
                .style("stroke-opacity", "0.7");

            const groupBars = g.selectAll(".group-bar")
                .data(chartData)
                .enter().append("g")
                  .attr("class", "group-bar")
                  .attr("transform", d => `translate(${xScaleGroups(d.group)},0)`);

            groupBars.selectAll("rect")
                .data(d => subgroups.map(key => ({ key: key, value: d.values[key] })))
                .enter().append("rect")
                    .attr("x", d => xScaleSubgroups(d.key))
                    .attr("y", d => yScale(d.value))
                    .attr("width", xScaleSubgroups.bandwidth())
                    .attr("height", d => chartHeight - yScale(d.value))
                    .attr("fill", d => color(d.key))
                    .attr("rx", 2).attr("ry", 2);
            
            groupBars.selectAll(".bar-label")
                .data(d => subgroups.map(key => ({ key: key, value: d.values[key] })))
                .enter().append("text")
                .filter(d => d.value > 0) // Only show label if value > 0
                .attr("class", "chart-label")
                .attr("x", d => xScaleSubgroups(d.key) + xScaleSubgroups.bandwidth() / 2)
                .attr("y", d => yScale(d.value) + 12) // Position inside the bar from top
                .attr("text-anchor", "middle")
                .style("font-size", "9px")
                .style("fill", d => (d.key === 'CR' && d.value > 15) || (d.key === 'PR' && d.value > 15) ? "white" : "var(--sobi-dark-text)") // Adjust text color for visibility
                .text(d => `${d.value.toFixed(1)}%`);
            
            // Add ORR text above grouped bars
            chartData.forEach(d => {
                g.append("text")
                    .attr("class", "chart-label orr-label")
                    .attr("x", xScaleGroups(d.group) + xScaleGroups.bandwidth() / 2)
                    .attr("y", yScale(d.orr) - 5) // Position above the total ORR stack
                    .attr("text-anchor", "middle")
                    .style("font-size", "9px")
                    .style("font-weight", "bold")
                    .style("fill", "var(--sobi-dark-blue)")
                    .text(`ORR: ${d.orr.toFixed(1)}%`);
            });
            
            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2)
                .attr("text-anchor", "middle")
                .style("font-size", "14px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);

            const legendData = subgroups.map(key => ({
                label: key,
                color: color(key)
            }));

            const legendItems = legendContainer.selectAll(".legend-item")
                .data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }
        
        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => {
                    clearTimeout(timeout);
                    func(...args);
                };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawPF984Chart = debounce(() => drawGroupedBarChartForPF984("#polaRchpPolarixIneligibleResponseChart", "#polaRchpPolarixIneligibleResponseLegend"), 250);
        
        window.addEventListener('resize', debouncedDrawPF984Chart);
        
        document.addEventListener('DOMContentLoaded', () => {
            debouncedDrawPF984Chart();
        });
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawPF984Chart, 0); 
        }
    </script>
</body>
</html>
